Ozempic vs. Wegovy: Same Drug, Different Doses — Which Is Right for You?

Ozempic and Wegovy contain the exact same active ingredient — semaglutide — yet they are approved for entirely different purposes, prescribed at different doses, and covered by insurance under different rules. Understanding the distinction is essential for any patient or clinician navigating the GLP-1 landscape.

The short answer: Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved for type 2 diabetes management. Wegovy (semaglutide 0.25 mg to 2.4 mg) is FDA-approved for chronic weight management. The maximum dose of Wegovy (2.4 mg weekly) is higher than the maximum approved dose of Ozempic (2 mg weekly), which is why Wegovy produces greater average weight loss in clinical trials.

At a Glance: Ozempic vs. Wegovy

How Semaglutide Works

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of GLP-1, a gut hormone released after eating that signals the pancreas to release insulin, tells the liver to stop releasing glucose, and — critically — acts on the brain's appetite centers to reduce hunger and slow gastric emptying.

The weight loss effect of semaglutide is not a side effect of blood sugar control. It is a direct pharmacological action on hypothalamic appetite circuits. This is why higher doses produce greater weight loss: more receptor activation in the brain means stronger appetite suppression.

The Dose Difference Explains the Weight Loss Difference

The SUSTAIN trials (Ozempic's pivotal diabetes trials) used doses up to 1 mg weekly and showed average weight loss of approximately 4–6 kg (roughly 4–6% of body weight). The STEP trials (Wegovy's pivotal obesity trials) used the 2.4 mg dose and showed average weight loss of approximately 15% of body weight over 68 weeks — more than double the effect seen with lower doses.

This is not a different drug producing a different effect. It is the same drug at a higher dose producing a stronger version of the same effect. The dose-response relationship for semaglutide's weight loss effect is steep and continues up to at least 2.4 mg weekly.

STEP 1 Trial Results (Wegovy 2.4 mg)

In the landmark STEP 1 trial published in the New England Journal of Medicine in 2021, 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity were randomized to semaglutide 2.4 mg weekly or placebo for 68 weeks. Key findings:

• Average weight loss: 14.9% of body weight with semaglutide vs. 2.4% with placebo
• 69.1% of participants lost ≥10% of body weight
• 50.5% lost ≥15% of body weight
• 32.0% lost ≥20% of body weight

These results were unprecedented for a non-surgical weight loss intervention and led to FDA approval of Wegovy in June 2021.

FDA Approvals: What Each Drug Is Cleared For

Ozempic (approved 2017)

Ozempic is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is also approved to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease, based on the SUSTAIN-6 trial.

Ozempic is not FDA-approved for weight loss. When physicians prescribe it for weight management in patients without diabetes, that is an off-label use — legal and common, but not the approved indication.

Wegovy (approved 2021, cardiovascular indication added 2024)

Wegovy is approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with:

• BMI ≥30 kg/m², or
• BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

In March 2024, the FDA expanded Wegovy's label to include cardiovascular risk reduction — specifically, reducing the risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke in adults with obesity or overweight and established cardiovascular disease. This was based on the SELECT trial, which enrolled 17,604 patients and showed a 20% relative risk reduction in major adverse cardiovascular events.

Insurance Coverage: The Critical Practical Difference

This is where the Ozempic vs. Wegovy distinction matters most for patients.

Ozempic is covered by most commercial insurance plans and Medicare Part D for patients with type 2 diabetes. Prior authorization is common but usually obtainable with a diabetes diagnosis and documented A1C.

Wegovy coverage is far more variable. Many commercial plans cover it for obesity, but Medicare Part D was prohibited from covering weight loss medications until the Treat and Reduce Obesity Act (TROA) passed. As of 2024, Medicare coverage for Wegovy for cardiovascular risk reduction (not obesity alone) became available under the expanded cardiovascular indication — but coverage for obesity without cardiovascular disease remains excluded under most Medicare plans.

The practical result: many patients with obesity but without diabetes or cardiovascular disease find Wegovy uncovered and pay the full list price of approximately $1,350/month. This is why some physicians prescribe Ozempic off-label for weight loss — it is the same drug at a lower dose, but covered under a diabetes diagnosis.

Insurance Coverage Summary

Side Effects: Are They Different?

Because both drugs contain semaglutide, the side effect profiles are essentially identical. The most common side effects are gastrointestinal:

• Nausea (very common, especially during dose escalation): affects approximately 44% of Wegovy patients and 20% of Ozempic patients in trials
• Vomiting: affects approximately 24% of Wegovy patients
• Diarrhea: affects approximately 30% of Wegovy patients
• Constipation: affects approximately 24% of Wegovy patients
• Abdominal pain: affects approximately 20% of Wegovy patients

The higher incidence of GI side effects with Wegovy compared to Ozempic reflects the higher dose, not a different drug. The slow titration schedule (starting at 0.25 mg and increasing every 4 weeks) is designed to minimize GI side effects during the adjustment period.

Serious but rare side effects (shared by both drugs):

• Pancreatitis (discontinue if suspected)
• Gallbladder disease (cholelithiasis and cholecystitis)
• Increased heart rate
• Diabetic retinopathy complications (in patients with pre-existing retinopathy)
• Thyroid C-cell tumors (observed in rodent studies; human relevance uncertain; contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2)

Who Should Take Ozempic vs. Wegovy?

Choose Ozempic if:

• You have type 2 diabetes and need glycemic control
• You have type 2 diabetes and established cardiovascular disease
• Your insurance covers Ozempic for diabetes but not Wegovy for obesity
• You are already on Ozempic for diabetes and experiencing weight loss as a secondary benefit

Choose Wegovy if:

• Your primary goal is weight loss and you do not have type 2 diabetes
• You have obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity
• You have established cardiovascular disease and obesity (the SELECT trial indication)
• Your insurance covers Wegovy for obesity or cardiovascular risk reduction

The off-label reality:

Many patients with obesity but without diabetes are prescribed Ozempic off-label because it is cheaper, more available (Wegovy has experienced supply shortages), or covered by their insurance under a diabetes-adjacent diagnosis. This is a pragmatic clinical decision, not an unsafe one — the drug is the same — but patients should understand they are receiving a lower maximum dose than the approved obesity treatment.

Availability and Supply

Ozempic and Wegovy have both experienced significant supply shortages since 2022, driven by demand that far outpaced manufacturing capacity. Novo Nordisk has invested heavily in expanding production, and availability has improved substantially by 2025–2026, but shortages at specific doses can still occur regionally.

The FDA's drug shortage database is the authoritative source for current availability. GoodRx and Mark Cuban's Cost Plus Drugs can help locate pharmacies with stock.

The Bottom Line

Ozempic and Wegovy are the same molecule at different doses for different indications. If you have type 2 diabetes, Ozempic is the indicated choice. If your primary goal is weight loss and you meet the obesity criteria, Wegovy at 2.4 mg is the approved, higher-dose option that produces greater average weight loss. The insurance and cost landscape is the primary practical driver of which drug a patient actually receives.

For a full comparison of all GLP-1 medications — including tirzepatide (Mounjaro/Zepbound), liraglutide (Victoza/Saxenda), and dulaglutide (Trulicity) — see the GLP-1 drug class guide. For current pricing and savings programs, see the semaglutide cost page.

Sources

1. FDA. Ozempic (semaglutide) Prescribing Information. Novo Nordisk, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020lbl.pdf
2. FDA. Wegovy (semaglutide) Prescribing Information. Novo Nordisk, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. https://doi.org/10.1056/NEJMoa2032183
4. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232. https://doi.org/10.1056/NEJMoa2307563
5. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834-1844. https://doi.org/10.1056/NEJMoa1607141